Pfizer says a third dose can "power boost" protection against the Dalta variant

U.S. pharmacologist Pfizer released Wednesday against the third dose of its vaccine COVID-19 According to preliminary data from a study, protection against the delta variant of the corona virus against a two-dose schedule can be “strongly enhanced”.

See: Covit-19 | The delta variant is as contagious as the chicken box

The company pointed out in a presentation that its data suggest that it is producing a third dose Five times higher levels of antibodies against delta variation Doses after the second dose were 11 times higher compared to those aged 18 to 55 years and those aged 65 to 85 years.

According to a document used by the company in a conference call to discuss quarterly financial results, Pfizer calculates that the neutrality of the delta variance can be increased by 100 compared to the two-dose schedule.

See: Covit-19 | Israel is starting to vaccinate people over the age of 60 with a third dose

As explained by the conference executives, Pfizer believes “May be required Third booster dose Maintain high levels of protection between 6 and 12 months after full vaccination “ Against Covit-19, they commented that the delta was a variant “Very spread” Saw so far.

This study is ongoing and has not been subjected to peer review, The second is that the third dose given at least half a year later is well tolerated and produces high levels of antibodies against the original corona virus and beta variant.

See: Govit-19: How to appease vaccine suspicions

Pfizer said it would like to apply for US Food and Drug Administration (FDA) approval earlier this month to deliver the third dose of the corona virus vaccine developed with the German company Bioendech.

“Companies hope to publish more concise data in the analysis and all the data collected will be there Shared as part of discussions with the FDA and EMA (European Pharmaceuticals Company) and other regulators in the coming weeks ”, The pharmacist noted in a note.

On the other hand, Pfizer CEO Albert Powerla told CNBC that the company had prepared a study showing that the effectiveness of two doses of the corona virus vaccine dropped to 84% after four to six months. Management

Specific, Its maximum efficiency is 96.2%, A point that decreases by an average of 6% every two months between the first week and two months of vaccination, the study points out, has not yet been reviewed and 44,000 people participated in the United States and other countries.

Powerla noted though The vaccine initially protects against hospitalization 100% corona virus, that percentage drops to 90% after six months Has a complete guide.

By criteria

Learn more